相关实验视频

Updated: Jul 4, 2025

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

纳米技术支持的M2巨分化和ferroptosis抑制,用于向性炎症性肠病治疗

Yuge Zhao¹, Weimin Yin¹, Zichen Yang¹

¹Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.

Journal of controlled release : official journal of the Controlled Release Society

|January 26, 2024

概括

这项研究开发了一种新型纳米抑制剂,通过促进抗炎M2巨分化和抑制铁死来增强炎性肠病 (IBD) 治疗,在体内显示出更好的治疗效果.

科学领域:

生物医学工程生物医学工程
纳米医学是一种纳米医学.
免疫学免疫学免疫学

背景情况:

炎症性肠病 (IBD) 治疗可以通过将巨细胞转化为抗炎M2表型来改善.
M2巨细胞表现出高的铁灭敏感性,限制了它们的治疗疗效.
同时促进M2两极化和抑制铁化对于有效的IBD治疗至关重要.

研究的目的:

开发一种新的纳米输送系统,以向M2巨细胞输送铁灭抑制剂.
研究促进M2极化和抑制IBD治疗中的ferroptosis的协同效应.
在IBD模型中评估开发的纳米抑制剂的体内疗效.

主要方法:

制造碳酸 (CaCO3) 矿化脂质体,封装一个铁灭抑制剂 (Fer-1),称为CaCO3@Lipo@Fer-1 (CLF).
研究Ca2+释放机制及其在通过CaSR/AKT/β-catenin通路促进M2极化中的作用.
评估铁-1释放及其对M2巨细胞铁亡的作用,包括GSH和GPX4上调和反应性氧物种清理.
通过表皮质增强透性和保留 (eEPR) 效应和治疗疗效在IBD病变中的CLF向效率的体内评估.

主要成果:

临床肺炎证明了对IBD病变的增强向效率 (约. 4.17倍) 通过eEPR效应.
通过高调节GSH和GPX4.4,CLF有效促进了M2巨细胞的两极分化,并抑制了铁亡.
在体内研究表明,CLF增加了M2/M1巨细胞比率和抑制了铁亡,从而改善了IBD治疗.

结论:

开发的CLF纳米抑制剂协同调节巨细胞极化和ferroptosis敏感性.
这一策略为增强IBD治疗提供了一种可行的方法.
针对性交付和CLF的双重作用机制对未来IBD治疗的发展充满希望.

关键词:

铁性化 (ferroptosis) 是一种炎症性肠病是一种炎症性肠病.巨细胞的两极分化矿物化的脂质细胞组.

更多相关视频

Depletion and Reconstitution of Macrophages in Mice

Depletion and Reconstitution of Macrophages in Mice

Published on: August 1, 2012

Metabolic Characterization of Polarized M1 and M2 Bone Marrow-derived Macrophages Using Real-time Extracellular Flux Analysis

Metabolic Characterization of Polarized M1 and M2 Bone Marrow-derived Macrophages Using Real-time Extracellular Flux Analysis

Published on: November 28, 2015

相关概念视频

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...